Feed SWDCF
SW

Swedencare AB (publ) SWDCF OTC · Healthcare · Sweden

$1.84 +0.00% +$0.00

Summary

50 / 100 · Bulios Score

What speaks for it

  • Revenue grew by 14% a year over the last 3 years.
  • It has been profitable 6 years in a row.

What to watch

  • The share price is above the Bulios Fair Price.
  • Earnings per share fell by 17% a year over the last 3 years.
  • It missed profit estimates 6 times in the last 8 quarters.
  • Operating profit covers the interest on its debt only 2.0 times.

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Score in detail

Price

Is it expensive?

Looks expensive
Bulios Fair Price
Overvalued Price today $1.84

By our assumptions the business is worth less than its shares cost today.

P/E today 34.8 65% lower
5-year average P/E 99.0
P/E today 34.8
Medical - Pharmaceuticals industry median

Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?

Today you pay 34.8 SEK for 1 SEK of yearly profit. Over the last five years it was 99.0 SEK on average.

Valuation in detail

Is it growing?

Slowly

Revenue (SEK)

Diluted EPS (SEK)

  • Analyst estimate

Revenue grew by 62% a year over 5 years. Over the last 3 years it grew by 14% a year. Earnings per share fell by 17% a year over the last 3 years.

Growth in detail

Does it make money?

Reasonably

Where 100 SEK of revenue goes

Net profit, industry median (Medical - Pharmaceuticals) 6.1 SEK

Out of every 100 SEK of revenue, 3.1 SEK is left as net profit.

Profitability in detail

Is it financially healthy?

Debt is a burden

Repaying all its debt would take 8.0 years of free cash flow. Its debt is larger than its cash.

Financial health in detail

Does it pay a dividend?

Small, stretched
Yield
1.65%
Paid out of profit
58%
Raised in a row
1 year

You receive $0.03 per share a year. The payout takes a large part of its profit or free cash flow.

Dividends in detail

What do analysts expect?

Mildly positive

Today's price within the analysts' price targets

The average target of $41 is 2,128% above today's price. 100% of the analysts recommend buying.

Analysts in detail

What does it earn on?

By product

The company reports no revenue by product.

By region

The company reports no revenue by region.

Segments in detail

We use essential cookies to run the website and optional analytics cookies to measure usage.

Privacy policy